Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 12:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–979 of 979 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Stability Clear all

Conditions: Stable Target INR
Interventions: Not listed
Lead sponsor: University of Arkansas; Other
Eligibility: 60 Years to 69 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Little Rock, Arkansas

Conditions: Type 1 Diabetes
Interventions: Xeris glucagon, Lilly glucagon; Drug
Lead sponsor: Steven J. Russell, MD, PhD; Other
Eligibility: 21 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Colorectal Cancer, Colorectal Cancer (CRC), Colorectal (Colon or Rectal) Cancer, CRC, Metastatic Colon Cancer, Colon Cancer, Advanced Colorectal Cancer
Interventions: CBI-1214; Biological
Lead sponsor: Cartography Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 10
States / cities: Phoenix, Arizona • Duarte, California • Los Angeles, California + 6 more

Conditions: Schizophrenia
Interventions: PF-03463275, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 37
States / cities: Cerritos, California • Chula Vista, California • Escondido, California + 26 more

Conditions: Healthy Volunteers, Schizophrenia
Interventions: TAK-041, TAK-041 Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Glendale, California

Conditions: Atherosclerosis
Interventions: MLDL1278A, placebo, statin, stable dose; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 22
States / cities: Torrance, California • Colorado Springs, Colorado • Washington D.C., District of Columbia + 15 more

Conditions: HIV Seropositivity
Interventions: Placebo, Rouvastatin calcium; Drug
Lead sponsor: Alison Morris; Other
Eligibility: 18 Years to 80 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 3
States / cities: Los Angeles, California • San Francisco, California • Pittsburgh, Pennsylvania

Conditions: Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor, Metastatic Cancer, WNT Pathway, HCC, Desmoid, Microsatellite Stable Colorectal Cancer, Metastatic Castration-resistant Prostate Cancer, Familial Adenomatous Polyposis (FAP), Endometrial Carcinoma, Prostate Cancer, Microsatellite Instability-High Colorectal Cancer, Adamantinomatous Craniopharyngioma
Interventions: FOG-001, mFOLFOX-6, Nivolumab, Trifluridine/tipiracil, Bevacizumab; Drug
Lead sponsor: Parabilis Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 619 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 31
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 25 more

Conditions: Healthy or Stable Underlying Chronic Medical Condition
Interventions: Q/LAIV (MEDI3250), FluMist/B/Yamagata, FluMist/B/Victoria; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 1,800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 18
States / cities: Sacramento, California • San Diego, California • San Francisco, California + 15 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin 100 mg, Canagliflozin 50 mg, Canagliflozin 300 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 13
States / cities: Little Rock, Arkansas • Los Angeles, California • Aurora, Colorado + 10 more

Conditions: Epilepsy, Seizures, Bipolar Disorder, Bipolar Depression
Interventions: Extended Release Lamotrigine; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 65 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 1,692 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 193
States / cities: Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 155 more

Conditions: Rheumatoid Arthritis
Interventions: JNJ-38518168 / MTX; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 4
States / cities: Anniston, Alabama • Daytona Beach, Florida • Duncansville, Pennsylvania + 1 more

Conditions: Kidney Transplant
Interventions: Belatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 8
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 4 more

Conditions: Critical Limb Ischemia, Severe Leg Ischemia, Peripheral Artery Disease, Peripheral Vascular Disease
Interventions: MESENDO, Placebo; Biological
Lead sponsor: TCA Cellular Therapy; Industry
Eligibility: 19 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Covington, Louisiana

Conditions: IUGR, Pregnancy
Interventions: Mannose, Myoinositol, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2016
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Parental Infant Bonding, Cardio-respiratory Stability in Preterm NICU Infants
Interventions: Parental Reading Aloud; Other
Lead sponsor: Georgetown University; Other
Eligibility: 7 Days to 40 Weeks
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Schizophrenia
Interventions: Drug: EVP-6308, Placebo; Drug
Lead sponsor: FORUM Pharmaceuticals Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Heart Diseases, Heart Failure, Myocardial Infarction, Chronic Stable Angina, Coronary Artery Bypass, Angioplasty
Interventions: Mindfulness-Based Stress Reduction (MBSR).; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 21 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Improving Anticoagulant Therapy Through Warfarin Metabolite Profiling

Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)

Statins for Pulmonary and Cardiac Complications of Chronic HIV - Coordinating Center

FOG-001 in Locally Advanced or Metastatic Solid Tumors

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus

Determination of Absorption and Elimination of Lamotrigine-XR

Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

A Study to Investigate How JNJ-38518168 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants

Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant Recipients

Phase II Combination Stem Cell Therapy for the Treatment of Severe Leg Ischemia

Transplacental Gradients and Transport in Intrauterine Growth Restricted (IUGR) Pregnancies Compared to Normal Pregnancies.

Effects of Reading to Preterm Infants on Baby and Parents' Well Being

Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics

Mindfulness & Stress Management Study for Cardiac Patients